What is Lexiscan?
Lexiscan, known chemically as regadenoson, is a pharmaceutical agent used to induce pharmacologic stress during myocardial perfusion imaging (MPI) [1]. It is a selective A2A adenosine receptor agonist, meaning it primarily targets and activates a specific type of adenosine receptor in the heart [2]. This activation leads to vasodilation, or widening, of the coronary arteries, increasing blood flow to the heart muscle [3]. This effect mimics the blood flow response seen during exercise stress testing, allowing physicians to detect blockages in the coronary arteries that may not be apparent at rest [4].
How does Lexiscan work?
Lexiscan works by binding to the A2A adenosine receptors found on the smooth muscle cells of the coronary arteries [2]. Upon binding, it triggers a cascade of intracellular events that result in the relaxation of these smooth muscle cells. This relaxation causes the arteries to dilate, increasing the diameter and capacity for blood flow. In individuals with narrowed coronary arteries due to atherosclerosis, this vasodilation is less pronounced or absent in the affected areas, creating a disparity in blood flow that can be detected by MPI [3][4].
What is adenosine and how does it differ from Lexiscan?
Adenosine is a naturally occurring nucleoside in the body that also acts as a vasodilator. In a medical context, adenosine is also used for pharmacologic stress testing in MPI [5]. The key difference between Lexiscan and adenosine lies in their receptor selectivity and duration of action. Adenosine is a non-selective agonist, affecting multiple adenosine receptor subtypes (A1, A2A, A2B, A3), though it primarily works through A2A receptors for vasodilation [6]. Lexiscan, on the other hand, is highly selective for the A2A receptor [2]. This selectivity is thought to lead to a more predictable and potentially safer vasodilation response [7]. Lexiscan also has a shorter half-life than adenosine, meaning it is cleared from the body more quickly, potentially reducing the duration of side effects [8].
How are Lexiscan and adenosine administered for stress testing?
Both Lexiscan and adenosine are administered intravenously. Lexiscan is given as a rapid bolus injection over 10 seconds [1]. Adenosine, however, is typically administered as a continuous infusion over several minutes [5]. The different administration methods contribute to their distinct pharmacokinetic profiles and the management of potential side effects.
What are the potential side effects of Lexiscan and adenosine?
Common side effects reported for both Lexiscan and adenosine include flushing, shortness of breath (dyspnea), chest discomfort, headache, and dizziness [1][5]. Arrhythmias, such as atrioventricular block and sinus bradycardia, can also occur [1][5]. Due to its selectivity and administration method, Lexiscan's side effects are generally expected to be of shorter duration than those of adenosine [8].
When does Lexiscan's patent expire?
Information regarding the specific patent expiration dates for Lexiscan (regadenoson) is available through resources that track pharmaceutical patents. For detailed information on patent exclusivity and potential generic entry, DrugPatentWatch.com provides comprehensive data [9].